Sodium valproate in tardive dyskinesia

D. E. Casey, J. P. Hammerstad

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Recent findings suggest that tardive dyskinesia may involve GABA-ergic influences in addition to dopaminergic receptor hypersensitivity and relative cholinergic hypofunction. Sodium valproate, which may increase brain GABA, moderately reduced tardive dyskinesia with doses of 900-3000 mg/day, as measured by a tremor-graph and rating scales. There was no correlation between dosage, blood levels, or clinical response. Although the symptoms were not completely controlled, valproate and other GABA-ergic agents may be useful compounds in studying and treating tardive dyskinesia.

Original languageEnglish (US)
Pages (from-to)483-485
Number of pages3
JournalJournal of Clinical Psychiatry
Volume40
Issue number11
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Sodium valproate in tardive dyskinesia'. Together they form a unique fingerprint.

  • Cite this